Jubilant Pharmova Limited (BOM:530019)

Market Cap	156.06B +11.7%
Revenue (ttm)	82.80B +14.4%
Net Income	3.99B -52.5%
EPS	25.08 -52.5%
Shares Out	158.40M
PE Ratio	39.28
Forward PE	26.17
Dividend	5.00 (0.51%)
Ex-Dividend Date	Jul 24, 2026

Volume	5,914
Open	996.50
Previous Close	1,007.10
Day's Range	983.40 - 996.50
52-Week Range	783.75 - 1,250.00
Beta	0.51
Analysts	Strong Buy
Price Target	1,244.00 (+26.26%)
Earnings Date	May 22, 2026

About Jubilant Pharmova

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary ...

• Industry: Pharmaceutical Preparations
• Founded: 1978
• Employees: 5,547
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 530019

Financial Performance

In fiscal year 2026, Jubilant Pharmova's revenue was 82.80 billion, an increase of 14.45% compared to the previous year's 72.35 billion. Earnings were 3.99 billion, a decrease of -52.53%.